

## Vaccine Candidates with Published Results from Phase 1-3 Clinical Trials

*Last updated: December 2, 2020*

Compound Name	Sponsor	Type of Vaccine	Funding Source	Current Trial Phase	Publications
<b>Ad5-nCoV</b>	CanSino Biologics	Adenovirus Type 5 Vector	CanSino Biologics	Phase 3	Phase 2 <a href="#">Zhu, August 2020</a>  Phase 1 <a href="#">Zhu, June 2020</a>
<b>AZD1222 (formerly ChAdOx1 nCoV-19)</b>	Oxford University, AstraZeneca, IQVIA, Serum Institute of India	Weakened adenovirus	Operation Warp Speed, UK Ministry of Health, Oxford University, BARDA	Phase 2/3	Phase 3 <a href="#">Interim Analysis Press Statement</a>  Phase 2/3 <a href="#">Ramasamy, November 2020</a>  Phase 1/2a <a href="#">Folegatti, August 2020</a>
<b>BNT162</b>	Pfizer, BioNTech	Lipid nanoparticle-formulated, nucleoside-modified mRNA	Pfizer, BioNTech	Phase 3	Phase 3 <a href="#">Final Efficacy Analysis Press Statement</a>  Phase 1/2 <a href="#">Walsh, October 2020</a> ; <a href="#">Mulligan, August 2020</a>
<b>Coronavac (formerly PiCoVacc)</b>	Sinovac	Inactivated SARS-CoV-2 with aluminum hydroxide adjuvant	Sinovac	Phase 3	Phase 1/2 <a href="#">Zhang, August 2020</a>
<b>Inactivated COVID-19</b>	Wuhan Institute of Biological Products, Sinopharm	Inactivated SARS-CoV-2	China Ministry of Science and Technology	Phase 3	Phase 1/2 <a href="#">Xia, August 2020</a>
<b>mRNA-1273</b>	Moderna	Lipid nanoparticle - encapsulated mRNA	Operation Warp Speed, NIAID, BARDA	Phase 3	Phase 3 <a href="#">Primary Efficacy Analysis Press Statement</a>  Phase 1/2 <a href="#">Anderson,</a>

					<a href="#">September 2020;</a> <a href="#">Jackson, July 2020</a>
<b>NVX-CoV2373</b>	Novavaxx	Recombinant SARS-CoV-2 glycoprotein nanoparticle adjuvanted with Matrix M	Novavax, CEPI, Department of Defense	Phase 2b	Phase 1/2 <a href="#">Keech, September 2020</a>
<b>Gam-COVID-Vac Lyo/ Gam-COVID-Vac</b>	Gamaleya Research Institute of Epidemiology and Microbiology, Russian Ministry of Health	Recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5) vector	Russian Ministry of Health	Phase 2	Phase 1/2 <a href="#">Logunov, September 2020</a>
<b>BBIBP-CorV</b>	Sinopharm	Inactivated SARS-CoV-2	China's National Program on Key Research, National Mega Projects for Major Infectious Diseases, National Mega Projects for New Drug Creation, Beijing Science and Technology Plan	Phase 1/2	Phase 1/2 <a href="#">Xia, October 2020</a>